Navigation Links
ACRES Announces Strategic Alliance with Atlantis Global Research Institute
Date:9/26/2013

Cambridge, Massachusetts (PRWEB) September 26, 2013

The Atlantis Global Research Institute (AGRI) today announced that it will work with the Alliance for Clinical Research Excellence and Safety (ACRES) to accelerate development of the ACRES Global Network, a group of high performing sites connected through a shared technology platform as part of an open and global system for clinical research. To that end, AGRI has joined ACRES as a Strategic Alliance partner and will immediately begin registering all of its global research sites in the ACRES network.    

AGRI Managing Director, Robert Wallace, noted, “We are elated to become an ACRES Alliance member and to have our national and international research sites join the ACRES global network. We believe that medical innovation and progress come from the formation of synergistic partnerships that enable conduct of clinical trials globally through a centralized process and, most importantly, provide access to novel treatment options to patients across the globe. Our alliance with ACRES allows this vision to become a reality.”

AGRI has developed a proprietary structure that allows the bio-pharmaceutical, pharmaceutical, device and diagnostic industry to conduct their clinical trials in a more time and cost-efficient manner. AGRI’s methodology is propelling the clinical trial industry forward by reducing the overall time and costs involved with conducting clinical trials.

Founded in 2012 AGRI has already established itself as one of the fastest growing and most innovative global research institutes worldwide, with over 100 research sites across the globe.

“Like ACRES, AGRI is a young and rapidly growing organization, and we share a new vision for the future of clinical research,” said ACRES President and CEO, Dr. Greg Koski. “We are delighted that AGRI is among the first global clinical research organizations to partner with ACRES to begin building a truly global system of research sites dedicated to enhancing excellence and safety in clinical trials world-wide for the benefit of all.”

About ACRES

ACRES, a global non-profit organization based in Cambridge, Massachusetts, is working in the public interest to build a comprehensive, sustainable and shareable global system for clinical research. By bringing together experts, stakeholders and like-minded organizations, ACRES is creating and implementing systems solutions that will enhance safety, data quality and integrity in an efficient, collaborative and cost effective manner to improve the health and lives of people everywhere.

About AGRI

Atlantis Global Research Institute (AGRI) is pioneering changes in how global clinical research is conducted by developing synergistic partnerships, collaborations, and alliances to produce quality results in a more timely and cost-efficient manner.

Read the full story at http://www.prweb.com/releases/GregKoskiACRES/biomedicalpharmaresearch/prweb11149403.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ACRES Launches Global Clinical Research Network Technology Platform
2. Pipette.com Announces Promotional T-Shirt and Other Specials for Neuroscience 2013
3. Cato Research Announces New Hires of Strategic Business Development Personnel
4. Gentris Corporation Partners with BioFortis, Announces New Vice President of Information Technology
5. Pets Best Insurance Announces Stem Cell Therapy and Regenerative Veterinary Medicine by Vet-Stem, Inc. Covered by Their Pet Health Insurance
6. Senomyx Announces Management Update
7. DTRA/SCC-WMD Announces $1 Million Algorithm Challenge Winner
8. Thermax Inc. Announces Price Increase on Ion Exchange Resins
9. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
10. Harwood Feffer LLP Announces Investigation of Verenium Corporation
11. Applied Integrin Sciences, Inc. Announces Exceptional Results In Ovarian Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):